Richard A. Heyman Sells 2,825 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 2,825 shares of the company's stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $77,715.75. Following the transaction, the director now directly owns 125,760 shares of the company's stock, valued at approximately $3,459,657.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Enliven Therapeutics Stock Performance

ELVN traded up $0.56 on Tuesday, reaching $28.01. 174,035 shares of the company's stock were exchanged, compared to its average volume of 261,678. The company's 50 day moving average is $23.26 and its 200-day moving average is $22.15. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -14.51 and a beta of 1.10. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $28.51.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.17. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research analyst reports. Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They set an "outperform" rating and a $32.00 price objective for the company. Baird R W raised shares of Enliven Therapeutics to a "strong-buy" rating in a research note on Tuesday, June 11th. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC boosted its holdings in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company's stock worth $37,000 after acquiring an additional 742 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock valued at $140,000 after buying an additional 3,189 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock valued at $646,000 after buying an additional 8,540 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics during the 1st quarter valued at approximately $167,000. Finally, SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $256,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.